Alnylam Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
ALNY Alnylam Pharmaceuticals Inc
NUV Nuveen Municipal Value Fund
NNBR NN Inc
WAT Waters Corp
ADP Automatic Data Processing Inc
CLABF Core One Labs Inc
FRHLF Freehold Royalties Ltd
WDAY Workday Inc
ENVX Enovix Corp
ENB Enbridge Inc
Go

Health Care : Biotechnology | Mid Cap Growth
Company profile

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's commercial products and pipeline of investigational ribonucleic acid (RNA) interference (RNAi) therapeutics are focused in four strategic therapeutic areas (STArs): Genetic Medicines, Cardio-Metabolic Diseases, Hepatic Infectious Diseases and central nervous system/Ocular Diseases. The Company's RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). The ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin amyloidosis. The GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. The OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1. The Leqvio is used for the treatment of adults with hypercholesterolemia.

Closing Price
$148.50
Day's Change
0.50 (0.34%)
Bid
--
Ask
--
B/A Size
--
Day's High
152.42
Day's Low
142.69
Volume
(Light)
Volume:
457,129

10-day average volume:
740,048
457,129

Walmart Q3 Sam's Club same-store sales up 13.9%; FactSet consensus up 8.7%

7:06 am ET November 16, 2021 (MarketWatch)
Print
	

(END) Dow Jones Newswires

November 16, 2021 07:06 ET (12:06 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.